FDA names five compounded GLP-1 marketing claims it considers deceptive
The list gives patients a way to judge compounded GLP-1 advertising, since compounded drugs skip the approval and safety review that brand-name versions go through [1].
The Food and Drug Administration has drawn a line for telehealth sellers of compounded medicines. A new agency page lists five kinds of promotional statements about compounded drugs — GLP-1s among them — that the agency calls deceptive and against federal law [1].
The page is addressed to companies, not patients. In it, FDA says it is concerned that telehealth marketing of compounded drugs, including glucagon-like peptide-1 receptor agonists, can lead people to make health decisions on the strength of claims that are not true [1]. The agency also points readers to its warning letter database, where searching "telehealth" turns up letters already sent over such marketing [1]. How many of those letters exist, which companies received them and when they went out are not stated on the page [1].
The five claims FDA flags:
Branding that suggests the seller made the drug. A website should not imply, falsely or in a misleading way, that the telehealth company is the one doing the compounding [1].
Calling a compounded product "generic" or saying it is the same as an approved drug. FDA draws the distinction itself: generic drugs receive agency approval before they are sold, while compounded drugs do not [1].
Saying the product is FDA-approved or has been checked for safety and effectiveness. The agency says compounded drugs get no such review before they reach the market [1].
Saying the product is clinically proven to match an approved drug's results [1].
Saying the product comes from an FDA-approved or FDA-licensed pharmacy or outsourcing facility. FDA states plainly that it does not approve or license any facility [1].
FDA adds that it is watching promotional material closely and will keep acting to shield patients from claims that mislead [1].
Why it matters for patients
The distinction FDA is enforcing is regulatory, but it carries practical weight. A compounded GLP-1 has not been through the approval process that Ozempic, Wegovy and Rybelsus (semaglutide) or Mounjaro and Zepbound (tirzepatide) went through, and FDA does not review compounded versions for safety, effectiveness or quality before they are sold [1]. Advertising may be the main thing a patient has to go on when choosing where to buy, and the page identifies several claims likely to appear in that advertising as ones the agency rejects [1].
Read as a screen, the page suggests questions to ask of any ad: Does it call the product generic, or "the same as" a brand-name drug? Does it say FDA-approved, or imply the seller is the manufacturer? Does it promise results equal to an approved medicine? Does it point to an "FDA-licensed" pharmacy? FDA's position is that each of these statements misrepresents a compounded product's status [1].
The page discusses compounded drugs as a category and names GLP-1s as one area of concern. It does not evaluate any particular product, brand or company, and it makes no recommendation about whether to use one [1].
What happens next
FDA says its oversight of promotional materials will continue, without specifying what actions it will take or when [1]. No deadline, no roster of companies under scrutiny and no enforcement schedule appear on the page [1].
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.